Microbion Biosciences
WEBAbout Microbion. Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of difficult-to-treat infections, including chronic infections and antibiotic-resistant infections.
About Microbion
WEBAbout Microbion. Microbion is a clinical-stage pharmaceutical company developing a novel class of microbial bioenergetic inhibitors for the treatment of resistant and difficult to treat infections. Subscribe to Our Newsletter
News | Microbion
WEBMicrobion Corp. Granted US Patent for the Use of Inhaled Pravibismane for Pulmonary Infections. Mar 09 2023. Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections. Feb 03 2023. Microbion Corporation CEO to Present at the 2023 BIO CEO & Investor Conference. Nov 03 2022.
Microbion's Pravibismane Granted Second FDA Orphan Drug …
WEBJan 30, 2024 · Microbion's lead drug candidate, pravibismane, is the first product in this new class and has multiple novel modes of action, including potent broad spectrum anti-infective, antibiofilm, and...
Microbion's Pravibismane Granted Second FDA Orphan Drug …
WEBJan 30, 2024 · BOZEMAN, MT and VANCOUVER, BC, Jan. 30, 2024 /PRNewswire/ - Microbion Corporation today announced that the company has been granted a second orphan drug designation for its lead drug candidate,...
Microbion Corporation | LinkedIn
WEBMicrobion Corporation | 780 followers on LinkedIn. Developing a new class of therapeutics for the treatment of rare and serious diseases | Microbion is a clinical-stage pharmaceutical company...
Microbion Corporation Announces FDA Has Granted Fast Track …
WEBAug 4, 2016 · Microbion Corporation Announces FDA Has Granted Fast Track Designation to MBN-101 for the Adjunctive Treatment of Moderate and Severe Diabetic Foot Ulcer Infections. Marketwired. August 4, 2016.
Microbion's Pravibismane Granted Second FDA Orphan Drug
WEBJan 30, 2024 · BOZEMAN, MT and VANCOUVER, BC, Jan. 30, 2024 /PRNewswire/ - Microbion Corporation today announced that the company has been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections.
Microbion Corporation Initiates Phase 2 Clinical Study Evaluating ...
WEBMar 9, 2023 · BOZEMAN, Mont. and VANCOUVER, BC, March 9, 2023 /PRNewswire/ - Microbion Corporation today announced that a Phase 2, randomized, controlled study has been initiated to assess the safety and...
Microbion's Topical Pravibismane Phase 1b Moderate or Severe …
WEBApr 4, 2024 · Microbion Corporation. Apr 04, 2024, 08:05 ET. Share this article. Topical pravibismane was found to be safe and well-tolerated for all doses tested in subjects with moderate to severely...
Skip to content